Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Providers' Perspectives on Treating Patients With Thalassemia.

Radke T, Paulukonis S, Hulihan MM, Feuchtbaum L.

J Pediatr Hematol Oncol. 2019 Oct;41(7):e421-e426. doi: 10.1097/MPH.0000000000001573.

PMID:
31368920
2.

CE: Understanding the Complications of Sickle Cell Disease.

Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M.

Am J Nurs. 2019 Jun;119(6):26-35. doi: 10.1097/01.NAJ.0000559779.40570.2c.

PMID:
31135428
3.

Effectiveness of Clinical Decision Support Based Intervention in the Improvement of Care for Adult Sickle Cell Disease Patients in Primary Care.

Mainous AG 3rd, Carek PJ, Lynch K, Tanner RJ, Hulihan MM, Baskin J, Coates TD.

J Am Board Fam Med. 2018 Sep-Oct;31(5):812-816. doi: 10.3122/jabfm.2018.05.180106.

4.

The accuracy of hospital ICD-9-CM codes for determining Sickle Cell Disease genotype.

Snyder AB, Lane PA, Zhou M, Paulukonis ST, Hulihan MM.

J Rare Dis Res Treat. 2017;2(4):39-45. Epub 2017 Jul 28.

5.

CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell Disease.

Hulihan M, Hassell KL, Raphael JL, Smith-Whitley K, Thorpe P.

MMWR Morb Mortal Wkly Rep. 2017 Nov 24;66(46):1269-1271. doi: 10.15585/mmwr.mm6646a2.

6.

Emergency department utilization by Californians with sickle cell disease, 2005-2014.

Paulukonis ST, Feuchtbaum LB, Coates TD, Neumayr LD, Treadwell MJ, Vichinsky EP, Hulihan MM.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26390. Epub 2016 Dec 21.

7.

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Paulukonis ST, Eckman JR, Snyder AB, Hagar W, Feuchtbaum LB, Zhou M, Grant AM, Hulihan MM.

Public Health Rep. 2016 Mar-Apr;131(2):367-75.

8.

Attitudes toward Management of Sickle Cell Disease and Its Complications: A National Survey of Academic Family Physicians.

Mainous AG 3rd, Tanner RJ, Harle CA, Baker R, Shokar NK, Hulihan MM.

Anemia. 2015;2015:853835. doi: 10.1155/2015/853835. Epub 2015 Feb 22.

9.

Incidence of sickle cell trait--United States, 2010.

Ojodu J, Hulihan MM, Pope SN, Grant AM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1155-8.

10.

Public health surveillance of nonmalignant blood disorders.

Beckman MG, Hulihan MM, Byams VR, Oakley MA, Reyes N, Trimble S, Grant AM.

Am J Prev Med. 2014 Nov;47(5):664-8. doi: 10.1016/j.amepre.2014.07.025. Epub 2014 Sep 19.

11.

The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome.

Mainous AG 3rd, Tanner RJ, Hulihan MM, Amaya M, Coates TD.

Br J Haematol. 2014 Dec;167(5):720-3. doi: 10.1111/bjh.13053. Epub 2014 Jul 22. Review. No abstract available.

12.

State-based surveillance for selected hemoglobinopathies.

Hulihan MM, Feuchtbaum L, Jordan L, Kirby RS, Snyder A, Young W, Greene Y, Telfair J, Wang Y, Cramer W, Werner EM, Kenney K, Creary M, Grant AM.

Genet Med. 2015 Feb;17(2):125-30. doi: 10.1038/gim.2014.81. Epub 2014 Jul 3.

13.

Elevated transferrin saturation, health-related quality of life and telomere length.

Mainous AG 3rd, Wright RU, Hulihan MM, Twal WO, McLaren CE, Diaz VA, McLaren GD, Argraves WS, Grant AM.

Biometals. 2014 Feb;27(1):135-41. doi: 10.1007/s10534-013-9693-4. Epub 2013 Dec 15.

14.

The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Grosse SD, Boulet SL, Grant AM, Hulihan MM, Faughnan ME.

Genet Med. 2014 Jan;16(1):33-9. doi: 10.1038/gim.2013.66. Epub 2013 May 23.

15.

Telomere length and elevated iron: the influence of phenotype and HFE genotype.

Mainous AG 3rd, Wright RU, Hulihan MM, Twal WO, McLaren CE, Diaz VA, McLaren GD, Argraves WS, Grant AM.

Am J Hematol. 2013 Jun;88(6):492-6. doi: 10.1002/ajh.23438. Epub 2013 May 13.

16.

Transferrin saturation and hospital length of stay and mortality in Medicare beneficiaries.

Mainous AG 3rd, Diaz VA, Knoll ME, Hulihan MM, Grant AM, Wright RU.

J Am Geriatr Soc. 2013 Jan;61(1):132-6. doi: 10.1111/jgs.12044. Epub 2012 Dec 3.

17.

Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity.

Wang Y, Kennedy J, Caggana M, Zimmerman R, Thomas S, Berninger J, Harris K, Green NS, Oyeku S, Hulihan M, Grant AM, Grosse SD.

Genet Med. 2013 Mar;15(3):222-8. doi: 10.1038/gim.2012.128. Epub 2012 Sep 27.

18.

A national survey of hemochromatosis patients.

Mainous AG 3rd, Knoll ME, Everett CJ, Hulihan MM, Grant AM, Garrison C, Koenig G, Sayers C, Allen KW.

J Am Board Fam Med. 2012 Jul-Aug;25(4):432-6. doi: 10.3122/jabfm.2012.04.110259.

19.

Calcium channel blocker use and serum ferritin in adults with hypertension.

Mainous AG 3rd, Weinberg ED, Diaz VA, Johnson SP, Hulihan MM, Grant AM.

Biometals. 2012 Jun;25(3):563-8. doi: 10.1007/s10534-012-9536-8. Epub 2012 Mar 13.

PMID:
22411599
20.

Public health implications of sickle cell trait: a report of the CDC meeting.

Grant AM, Parker CS, Jordan LB, Hulihan MM, Creary MS, Lloyd-Puryear MA, Goldsmith JC, Atrash HK.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S435-9. doi: 10.1016/j.amepre.2011.09.012.

PMID:
22099370
21.

Iron overload: what is the role of public health?

Hulihan MM, Sayers CA, Grosse SD, Garrison C, Grant AM.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S422-7. doi: 10.1016/j.amepre.2011.09.020.

PMID:
22099368
22.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

23.

IRon Overload screeNing tool (IRON): development of a tool to guide screening in primary care.

Mainous AG 3rd, Diaz VA, Everett CJ, Knoll ME, Hulihan MM, Grant AM, McLaren CE, McLaren GD.

Am J Hematol. 2011 Sep;86(9):733-7. doi: 10.1002/ajh.22082. Epub 2011 Jul 28.

24.

Uric acid as a potential cue to screen for iron overload.

Mainous AG 3rd, Knoll ME, Everett CJ, Matheson EM, Hulihan MM, Grant AM.

J Am Board Fam Med. 2011 Jul-Aug;24(4):415-21. doi: 10.3122/jabfm.2011.04.110015.

25.

Characterization of DCTN1 genetic variability in neurodegeneration.

Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destée A, Krygowska-Wajs A, Chartier-Harlin MC, Ross OA, Rademakers R, Farrer MJ.

Neurology. 2009 Jun 9;72(23):2024-8. doi: 10.1212/WNL.0b013e3181a92c4c.

26.

DCTN1 mutations in Perry syndrome.

Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilariño-Güell C, Ross OA, Brown LA, Castanedes-Casey M, Dickson DW, Wszolek ZK.

Nat Genet. 2009 Feb;41(2):163-5. doi: 10.1038/ng.293. Epub 2009 Jan 11.

27.

ATP13A2 variability in Parkinson disease.

Vilariño-Güell C, Soto AI, Lincoln SJ, Ben Yahmed S, Kefi M, Heckman MG, Hulihan MM, Chai H, Diehl NN, Amouri R, Rajput A, Mash DC, Dickson DW, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Hum Mutat. 2009 Mar;30(3):406-10. doi: 10.1002/humu.20877.

28.

Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism.

Lee MJ, Mata IF, Lin CH, Tzen KY, Lincoln SJ, Bounds R, Lockhart PJ, Hulihan MM, Farrer MJ, Wu RM.

Mov Disord. 2009 Jan 15;24(1):104-8. doi: 10.1002/mds.22093.

PMID:
19006224
29.

Fine-mapping and candidate gene investigation within the PARK10 locus.

Haugarvoll K, Toft M, Skipper L, Heckman MG, Crook JE, Soto A, Ross OA, Hulihan MM, Kachergus JM, Sando SB, White LR, Lynch T, Gibson JM, Uitti RJ, Wszolek ZK, Aasly JO, Farrer MJ.

Eur J Hum Genet. 2009 Mar;17(3):336-43. doi: 10.1038/ejhg.2008.187. Epub 2008 Oct 15.

30.

Glucosidase-beta variations and Lewy body disorders.

Farrer MJ, Williams LN, Algom AA, Kachergus J, Hulihan MM, Ross OA, Rajput A, Papapetropoulos S, Mash DC, Dickson DW.

Parkinsonism Relat Disord. 2009 Jul;15(6):414-6. doi: 10.1016/j.parkreldis.2008.08.004. Epub 2008 Oct 1.

31.

Genetic variation of Omi/HtrA2 and Parkinson's disease.

Ross OA, Soto AI, Vilariño-Güell C, Heckman MG, Diehl NN, Hulihan MM, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ.

Parkinsonism Relat Disord. 2008 Nov;14(7):539-43. doi: 10.1016/j.parkreldis.2008.08.003. Epub 2008 Sep 14.

32.

Pallidonigral TDP-43 pathology in Perry syndrome.

Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, Lechevalier B, Calne DB, Personett DA, Hulihan M, Kachergus J, Rademakers R, Baker MC, Grantier LL, Sujith OK, Brown L, Calne S, Farrer MJ, Wszolek ZK.

Parkinsonism Relat Disord. 2009 May;15(4):281-6. doi: 10.1016/j.parkreldis.2008.07.005. Epub 2008 Aug 23.

33.

PINK1 mutations and parkinsonism.

Ishihara-Paul L, Hulihan MM, Kachergus J, Upmanyu R, Warren L, Amouri R, Elango R, Prinjha RK, Soto A, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Neurology. 2008 Sep 16;71(12):896-902. doi: 10.1212/01.wnl.0000323812.40708.1f. Epub 2008 Aug 6.

34.

Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño-Güell C, Ross OA, Kolianov V, Yust-Katz S, Treves TA, Barhum Y, Hulihan M, Melamed E.

J Neural Transm (Vienna). 2008 Sep;115(9):1279-84. doi: 10.1007/s00702-008-0074-z. Epub 2008 Jul 30.

PMID:
18665323
35.

Genomic investigation of alpha-synuclein multiplication and parkinsonism.

Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ.

Ann Neurol. 2008 Jun;63(6):743-50. doi: 10.1002/ana.21380.

36.

LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.

Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Lancet Neurol. 2008 Jul;7(7):591-4. doi: 10.1016/S1474-4422(08)70116-9. Epub 2008 Jun 6. Erratum in: Lancet Neurol. 2008 Aug;7(8):675.

PMID:
18539535
37.

Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.

Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ.

Acta Neurol Scand. 2008 Nov;118(5):320-7. doi: 10.1111/j.1600-0404.2008.01019.x. Epub 2008 May 15.

PMID:
18485051
38.

Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.

Perez-Pastene C, Cobb SA, Díaz-Grez F, Hulihan MM, Miranda M, Venegas P, Godoy OT, Kachergus JM, Ross OA, Layson L, Farrer MJ, Segura-Aguilar J.

Neurosci Lett. 2007 Jul 18;422(3):193-7. Epub 2007 Jun 17.

39.

Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schüle B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ.

Neurology. 2007 Mar 20;68(12):916-22. Epub 2007 Jan 24.

PMID:
17251522
40.

Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ.

Neurogenetics. 2007 Apr;8(2):95-102. Epub 2007 Jan 16.

PMID:
17225181
41.

Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.

Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM.

Parkinsonism Relat Disord. 2007 Mar;13(2):89-92. Epub 2007 Jan 10.

PMID:
17222580
42.

Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.

Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ.

Mov Disord. 2007 Feb 15;22(3):389-92.

PMID:
17216639
43.

Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

JAMA. 2006 Aug 9;296(6):661-70.

PMID:
16896109
44.

Genomewide association, Parkinson disease, and PARK10.

Farrer MJ, Haugarvoll K, Ross OA, Stone JT, Milkovic NM, Cobb SA, Whittle AJ, Lincoln SJ, Hulihan MM, Heckman MG, White LR, Aasly JO, Gibson JM, Gosal D, Lynch T, Wszolek ZK, Uitti RJ, Toft M.

Am J Hum Genet. 2006 Jun;78(6):1084-8; author reply 1092-4. No abstract available.

45.

Lrrk2 R1441 substitution and progressive supranuclear palsy.

Ross OA, Whittle AJ, Cobb SA, Hulihan MM, Lincoln SJ, Toft M, Farrer MJ, Dickson DW.

Neuropathol Appl Neurobiol. 2006 Feb;32(1):23-5.

PMID:
16409550
46.

Lrrk2 pathogenic substitutions in Parkinson's disease.

Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ.

Neurogenetics. 2005 Dec;6(4):171-7. Epub 2005 Sep 17.

PMID:
16172858
47.

LRRK2 mutations in Parkinson disease.

Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM.

Neurology. 2005 Sep 13;65(5):738-40.

PMID:
16157908
48.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J.

Parkinsonism Relat Disord. 2005 Sep;11(6):349-52.

PMID:
16102999
49.

LRRK2 R1441G in Spanish patients with Parkinson's disease.

Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V.

Neurosci Lett. 2005 Jul 15;382(3):309-11. Epub 2005 Apr 13.

PMID:
15925109
50.

Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M.

Ann Neurol. 2005 May;57(5):762-5.

PMID:
15852371

Supplemental Content

Loading ...
Support Center